Colorectal cancer is recognized as the second leading cause of cancer-related deaths globally, with early detection significantly improving treatment outcomes. Traditional screening methods, particularly colonoscopies, present challenges such as high costs and discomfort, which may deter timely testing.
Researchers at the University of Geneva (UNIGE) have introduced a novel approach utilizing machine learning to create a comprehensive catalogue of human gut bacteria. This catalogue enables the detection of colorectal cancer through simple stool samples, offering a non-invasive and cost-effective alternative to colonoscopy. The findings, published in the journal Cell Host & Microbe, suggest that this method not only aids in cancer detection but also enhances understanding of how gut microbiota affects overall health.
The need for improved screening tools is underscored by the increasing incidence of colorectal cancer, particularly among younger adults. Many cases are diagnosed at advanced stages, limiting treatment options. Historically, while there has been awareness of the role gut microbiota plays in colorectal cancer, translating this knowledge into usable medical tools has proven difficult, largely due to the variability of bacterial strains and their differing impacts on health.
The UNIGE researchers focused on the subspecies level of microbiota, striking a balance between the general species analysis and the specific strain-level differences. This focus allows for a more precise understanding of bacterial functions related to disease.
The researchers successfully developed a model that, when tested with clinical datasets, identified 90% of colorectal cancer cases—comparable to the 94% detection rate of colonoscopies. Future clinical trials will further explore the method's effectiveness in identifying various cancer stages. Beyond cancer detection, this innovative approach may pave the way for non-invasive diagnostic tools for a range of health conditions based on microbiota analysis.